USANA HEALTH SCIENCES INC Form 10-Q November 07, 2012 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2012

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number: 0-21116

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Utah (State or other jurisdiction of incorporation or organization)	87-0500306 (I.R.S. Employer Identification No.)
3838 West	t Parkway Blvd., Salt Lake City, Utah 84120
(Addre	ess of principal executive offices, Zip Code)
	(801) 954-7100
(Registr	rant s telephone number, including area code)
	filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act horter period that the registrant was required to file such reports), and (2) has been subject No o
	mitted electronically and posted on its corporate Web site, if any, every Interactive Data ule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a larg company. See the definitions of large accelerated file	e accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting er, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer o	Accelerated filer x
Non-accelerated filer o	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The number of shares outstanding of the registrant s common stock as of November 1, 2012 was 14,425,692.

USANA HEALTH SCIENCES, INC.

FORM 10-Q

For the Quarterly Period Ended September 29, 2012

INDEX

		Page
	PART I. FINANCIAL INFORMATION	
Item 1	Financial Statements (unaudited)	
	Consolidated Balance Sheets	3
	Consolidated Statements of Comprehensive Income Quarter Ended	4
	Consolidated Statements of Comprehensive Income Nine Months Ended	5
	Consolidated Statements of Stockholders Equity	6
	Consolidated Statements of Cash Flows	7
	Notes to Consolidated Financial Statements	8 12
Item 2	Management s Discussion and Analysis of Financial Condition and Results of Operations	13 23
Item 3	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4	Controls and Procedures	23
	PART II. OTHER INFORMATION	
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 6	Exhibits	25 26
<u>Signatures</u>		27
	2	

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

ACCEPTEG		2012
ASSETS		
Current assets		
Cash and cash equivalents	\$ 50,353	\$ 76,601
Inventories	36,968	33,296
Prepaid expenses and other current assets	18,738	28,754
Total current assets	106,059	138,651
Property and equipment, net	60,754	62,052
Goodwill	17,740	17,797
Intangible assets, net	42,637	42,022
Deferred tax assets	11,033	6,705
Other assets	6,273	7,057
	\$ 244,496	\$ 274,284
LIABILITIES AND STOCKHOLDERS EQUITY		
Current liabilities		
· •	\$ 7,952	\$ 6,906
Other current liabilities	51,744	59,881
Total current liabilities	59,696	66,787
Deferred tax liabilities	9,948	9,571
Other long-term liabilities	942	946
Stockholders equity		
	15	14

Common stock, \$0.001 par value; Authorized 50,000 shares, issued and outstanding 14,940 as of December 31,2011 and 14,496 as of September 29,2012

us of Becember 51, 2011 und 11, 150 us of September 25, 2012		
Additional paid-in capital	49,257	49,263
Retained earnings	118,799	141,042
Accumulated other comprehensive income	5,839	6,661
Total stockholders equity	173,910	196,980
	\$ 244,496 \$	274,284

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

	Quarters Ended				
	October 1,	September 29,			
	2011		2012		
Net sales	\$ 143,501	\$	165,175		
Cost of sales	25,202		30,343		
C C	110 200		124 922		
Gross profit	118,299		134,832		
Operating expenses:					
Associate incentives	66,158		70,406		
Selling, general and administrative	33,365		40,342		
Total operating expenses	99,523		110,748		
	,		,		
Earnings from operations	18,776		24,084		
Other income (expense):					
Interest income	42		75		
Interest expense	(1)		(11)		
Other, net	92		203		
Other income (expense), net	133		267		
Earnings before income taxes	18,909		24,351		
Income taxes	6,524		6,861		
Net earnings	\$ 12,385	\$	17,490		
Earnings per common share					
Basic	\$ 0.82	\$	1.22		
Diluted	\$ 0.81	\$	1.18		
Weighted average common shares outstanding					
Basic	15,043		14,365		
Diluted	15,205		14,884		
Comprehensive income:					
Net earnings	\$ 12,385	\$	17,490		

Other comprehensive income (loss), net of tax:		
Foreign currency translation adjustment	(2,309)	1,312
Tax (expense) benefit related to foreign currency translation adjustment	1,051	(402)
Other comprehensive income (loss), net of tax	(1,258)	910
Comprehensive income	\$ 11,127	\$ 18,400

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

	Nine Mon October 1, 2011	onths Ended September 29, 2012			
Net sales	\$ 435,992	\$	480,196		
Cost of sales	77,072		85,633		
Gross profit	358,920		394,563		
Operating expenses:					
Associate incentives	198,725		209,316		
Selling, general and administrative	103,038		115,150		
Total operating expenses	301,763		324,466		
Earnings from operations	57,157		70,097		
Other income (expense):					
Interest income	146		184		
Interest expense	(9)		(11)		
Other, net	97		4		
Other income (expense), net	234		177		
Earnings before income taxes	57,391		70,274		
Income taxes	19,800		22,288		
Net earnings	\$ 37,591	\$	47,986		
Earnings per common share					
Basic	\$ 2.43	\$	3.27		
Diluted	\$ 2.39	\$	3.19		
Weighted average common shares outstanding					
Basic	15,495		14,673		
Diluted	15,712		15,064		
Comprehensive income:					
Net earnings	\$ 37,591	\$	47,986		

Other comprehensive income (loss), net of tax:		
Foreign currency translation adjustment	272	1,156
Tax (expense) benefit related to foreign currency translation adjustment	491	(334)
Other comprehensive income (loss), net of tax	763	822
Comprehensive income	\$ 38,354	\$ 48,808

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

Nine Months Ended October 1, 2011 and September 29, 2012

(in thousands)

(unaudited)

	Commo	on Stock	lue	Additional Paid-in Capital	Retained Earnings	Accumulated Other omprehensive Income	Total
For the Nine Months Ended	Shares	va	iue	Сарпаі	Laimigs	Hicome	Total
October 1, 2011							
Balance at January 1, 2011	15,985	\$	16	\$ 51,222	\$,	\$ 5,357	\$ 146,802
Net earnings					37,591		37,591
Other comprehensive income, net of tax						763	763
Equity-based compensation expense				7,739			7,739
Common stock repurchased and retired	(1,095)		(1)	(11,072)	(21,628)		(32,701)
Common stock issued under equity award plans, including tax expense of							
\$309	64			(270)			(270)
Tax impact of canceled vested equity							
awards				(785)			(785)
Balance at October 1, 2011	14,954	\$	15	\$ 46,834	\$ 106,170	\$ 6,120	\$ 159,139
For the Nine Months Ended							
September 29, 2012							
Balance at December 31, 2011	14,940	\$	15	\$ 49,257	\$ 118,799	\$ 5,839	\$ 173,910
Net earnings					47,986		47,986
Other comprehensive income, net of tax						822	822
Equity-based compensation expense				8,184			8,184
Common stock repurchased and retired	(877)		(1)	(9,757)	(25,743)		(35,501)
Common stock awarded to Associates	2			100			100
Common stock issued under equity award plans, including tax benefit of							
\$1,517	431			1,826			1,826
Tax impact of canceled vested equity							
awards				(347)			(347)
Balance at September 29, 2012	14,496	\$	14	\$ 49,263	\$ 141,042	\$ 6,661	\$ 196,980

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	C	Nine Mont October 1, 2011	ed September 29, 2012	
Cash flows from operating activities				
Net earnings	\$	37,591	\$ 47,986	
Adjustments to reconcile net earnings to net cash provided by operating activities				
Depreciation and amortization		6,361	6,608	
(Gain) loss on sale of property and equipment		44	(106)	
Equity-based compensation expense		7,739	8,184	
Excess tax benefits from equity-based payment arrangements		(48)	(2,779)	
Common stock awarded to Associates			100	
Deferred income taxes		(1,473)	2,255	
Changes in operating assets and liabilities:				
Inventories, net		(2,664)	4,462	
Prepaid expenses and other assets		6,063	(9,223)	
Accounts payable		2,614	(1,063)	
Other liabilities		(2,759)	7,199	
Total adjustments		15,877	15,637	
Net cash provided by operating activities		53,468	63,623	
Cash flows from investing activities				
Proceeds from sale of property and equipment		1	148	
Purchases of property and equipment				